New Leadership take charge at Dr. Datsons Labs Ltd, New Management to drive export market of Dr. Datsons’s branded generics.
Mr. Mahesh Vaidya takes charge as the Vice Chairman and Managing Director & Mr. Sameer Talim as the new Chief Executive officer.
Saturday, 14th February 2015, Mumbai, Maharashtra. In a major development to the top leadership change in the listed Pharma Company Dr. Datsons Labs Ltd, the announcement has come from the Meeting of the Board of Directors of the Company held on February 14, 2015. The salient features of the unaudited financial results seem to indicate a positive vibe as the sales is up 15% & net profit up from 1.97lakhs to 1.99 lakhs
Dr.Datsons Labs Ltd has informed BSE that the Board of Directors of the Company at its meeting held on February 14, 2015, inter alia, has decided to appoint Mr. Mahesh Vaidya, as the Vice Chairman and Managing Director of the Company w.e.f. February 14, 2015. Dr. Kannan Vishwanath, as the Vice Chairman and Managing Director of the Company has stepped down from the post w.e.f. February 14, 2015. Dr.Datsons Labs Ltd had earlier appointed Mr. Sameer Talim as the Chief Executive officer of the Company, with effect from February 09, 2015.
Sources to Pharmaleaders reveal that the appointment of Mr. Samir Talim as the CEO of Dr. Datsons Labs Ltd will be primarily to drive the company’s presence in the major markets & to aggressively build on the export orders, work on existing clients & as well as to generate new business give push to the Generic barands of Dr Datsons in Middle East, South East asia & South America. The new CEO will also push Registrations of our formulations & enter new markets using his expertise in these markets. Mr. Samir has wide exposures in the export markets based on his successful stints in the previous assignments will help Dr. Datsons Labs penetration into the key market. India ofcourse will remain as the Key market as the company still has big companies in Contract Manufacturing. Mr. Mahesh Vaidya as the new Vice-Chairman & Managing Director will aggressively look into equity raising for the company. Mr. Mahesh Vaidya is entrusted with the responsibilities to meet with the potential investors for stake sale or fresh infusions of funds into the company which is quite vital for the growth momentum of Dr. Datsons Labs. Ltd. There are key unfinished agenda as certain vital deals are yet to be given a finishing end including the current proposals to give new & fresh perspectives.
In an exclusive interview to Pharmaleaders ( www.pharmaleader.tv ), the new Vice-Chairman & MD, Mr Mahesh Vaidya expressed hope that the coming I year is going to be very crucial to the company’s both organic & inorganic growth as many deals, JV’s & partnership are pending for the final clearances, Dr. Datsons Labs will be closely looking at the operational efficiency of the Mahad Facility for Making APIs for Captive Use of APIs for their formulations. There are interesting & exciting times ahead of us, we all are committed to bring the company to its new height. Commenting on the state of india’s booming Pharma market, Mr Vaidya stated that India has become a prime destination for manufacture of branded, generic and branded generic medicines with a strong export element. It is estimated that around 40 per cent of the generic drugs in the US come from India and with Obamacare being introduced this figure is set to rise further. Overall market seems positive & our new CEO Mr. Sameer Talim will drive the domestic as well as the exports market, soon we will announce a breakthrough export deal that we have received from Nigeria & Yemen.
Mr. Sameer Talim stated that “Indian pharmaceutical companies have capitalised on export opportunities in regulated and semi-regulated markets and pharma exports from India grew at a CAGR in excess of 20% from 2006 to 2012. Currently, India is the third-largest exporter of Active Pharmaceutical Ingredients (APIs). Indian pharma exports are expected to bring in an estimated $40 billion by the First Quarter of 2015. With Indian products competing with their global counterparts in terms of quality, India has been able to establish a global footprint. Indian companies operating in the west have been able to do so successfully & Dr. Datsons Lab is fully equipped to meet the challenges both regulatory & operationally to cater to the world market. We are expecting a 30 % jump in exports in the second quarter which will largely be driven by the generic push”.
Mr Sameer Talim, CEO, Dr. Datsons Labs Ltd.
Mr Sameer Talim is an B.COM & MBA from Mumbai University with entire Experience Based in West Africa in Healthacare Marketing. He started as Management Trainee with Kinds Healthcare Limited Kampala & Rose to Become The Vice President Marketing & Operations at Sparkeway Industries in Kampala. In last 20 years he has extensive experience in West African Markets for marketing registration & Distribution of Anti Malarial Drugs, HIV & AIDS Medication. He has returned to India after 20 years due to person & domestic requirements. He has joined us & will spearhead our growth operations for Exports worldwide. Mr Sameer repeatedly produce sustained revenue and EBITA growth in dynamic and changing markets. Has proven achievements and Extensive business background in international, multi-cultural environments. Mr. Sameer is a results-oriented Healthcare CEO with over 25 years’ experience as a Senior Executive. Strong reputation in executive leadership, strategic planning, business development, fiscal and organizational management. Demonstrated results in quality management, revenue cycle improvement and financial turnarounds. Worked in both for-profit and not-for-profit healthcare organizations and systems. Superb decision making and problem solving skills. High-energy people-person with strong communication and interpersonal skills & a Senior executive with verifiable year-after-year success achieving revenue, profit, and business growth objectives within start-up, turnaround, and rapid-change environments. Extensive experience with highly engineered systems, which require deep understanding of critical business drivers in multiple markets and industries; highly successful in building relationships with upper-level decision makers, seizing control of critical problem areas, and delivering on customer commitments.
Mr Mahesh Vaidya
Vice Chairman & MD, Dr. Datsons Labs Ltd.
Mahesh Vaidya is a top Management Professional with over 25 years of experience in the field of Finance,Accounts, Overall Business Development. This dynamic young MD of Dr Datsons Labs, started his career with couple of Pharma Companies through his hardwork and dedication earned the highest position in the organisation. His leadership witnessed dramatic growth and through his aggressive positioning and strategy the organisation won many laurels and awards in past. As the new VC & MD of the company, Mahesh will spearhead Dr Datsons Labs’s’s aggressive game plan to accelerate growth and take advantage of the changing business dynamics that emphasize equally, aspects of product portfolio, quality, global footprint and cost efficiency. Mahesh has a meritorious track record, and the experience of managing large business operations earlier, with similar responsibilities.
Mr Mahesh Vaidya is BSC & MSc It from Pune University. He has over 25 years experience working in global markets . He started His career with Pharmed Europe Ltd looking into their Medical devices Business. He rose to Position of Head of commercial operations in one year looking into their entire exports of Medical devices worldwide. From Pharmed Limited Europe he Moved to Quibarkfarm Global S.A. As Director Exports to looking into entering generic markets in South America Till January 2015. He has been appointed as the Vice Chairman & Managing Director. Repeatedly produce sustained revenue and EBITA growth in dynamic and changing markets. Proven achievements and Extensive business background in international, multi-cultural environments. Senior executive with verifiable year-after-year success achieving revenue, profit, and business growth objectives within start-up, turnaround, and rapid-change environments. Extensive experience with highly engineered systems, which require deep understanding of critical business drivers in multiple markets and industries; highly successful in building relationships with upper-level decision makers, seizing control of critical problem areas, and delivering on customer commitments. Mr Vaidya has shown remarkable achievements in Excellent marketing skills, exceptional ability to communicate orally and in writing, has experience of sales metric designs & demonstrated ability to work in a leadership role. A far sighted individual withover 25 years’ experience in excellent business development skills with hands on knowledge of directing the activities of all projects. Excellent knowledge of supporting the company’s strategic alliances and participating in marketing strategies. Hands on experience of supervising employees across different departments in order to facilitate the process of production and marketing. Mr. Vaidya has hands on experience on operations management, Acquisitions & Integrations, Organic Business Growth,Strategic Planning Staff Development-Promotion, Performance & Quality Standards,Customer Satisfaction & Allegiance Leadership Development, P&L Management/Budget Planning, Engineering & Manufacturing Change Management, Commercial & Customer Support Strategic Partnerships. As Vice Chairman & Managing Director of Dr. Datsons Labs Ltd, Mr Mahesh Vaiday will be the driving spirit of leadership to the Board & will undertake strategic initiatives to propel the growth engine of the Company. Mr Mahesh Vaiday will have the responsibilities to identify and direct business development activities, ensure that all corporate objectives are pursued & organize activities for business development, develop strategic business plans, establish company culture, values and vision manage risk management plans.
About Dr. Datsons Lab Ltd
Dr. Datsons Lab Ltd, formerly known as Aanjaneya Lifecare Ltd, BSE code (533412) is a public listed vertically integrated company having state-of-the-art; WHO GMP approved facilities for manufacturing bulk drugs at Mahad and finished dosage forms at Pirungut near Pune. It is one of the largest contract manufacturers of codeine based cough syrups in India. The company exclusively manufactures the Codorex Brand of Zydus Cadilla and Codilite Brand of Tablets India Ltd. amongst others.The company raised about Rs. 117 crore from its IPO and the funds are being used to built new capacities along with the refurbishing of Research & Development centre. The new facilities being created as part of CAPEX are using eco friendly, recyclable material and will be rated by LEEDS once completed.The Facilities being established will comply with the latest European & US guidelines. With new capacities to be added in next 6 to 9 months the company will be expanding operations in emerging markets of South East Asia, Africa & South & Central America and its domestic operation in branded generics segment. The company with its manufacturing facilities –in Mahad, Hyderabad and Pune has to its credit many achievements. It is the world’s third-largest manufacturer of quinine salts in the world . Only nine companies globally manufacture quinine salts.One of the largest codeine based formlulations manufacturer in the pharmaceutical sector. One of the largest manufacturer of multi- flavored Lozenges in medical products in India. The company pioneered the recognition that lozenges represent a stable platform for the delivery of pharmaceutical and nutraceutical ingredients. Dr. Datson’s Nicco Nil lozenge is a first-of-its-kind hard boiled lozenge remedy for smoking de-addition; its Relacs is a first-time lozenge against insomnia and Arecta Plus, a lozenge variant for Erectile Dysfunction, is a first of its kind . The company has an expertise in opportunity spotting and innovation. The company’s success has been built on a business model that integrates Research, Innovation and Knowledge. The company has invested in building proprietary Knowledge through research and acquisitions. Dr. Datson’s competence has been validated through patents granted by international and Indian authorities. Production of Quinine Sulphate increased 30% in 2011-2012. Sales of Quinine Sulphate grew 45%. Exports increased 250% from Rs 10 Crore to Rs 31 crore. Added 35 international and 50 domestic clients. Completed trials for Bromexine(expectorant)a new API that will be launched in 2012-1023. Highlights 2011-2012 for Finished Dosage Forms. Launched ‘Rancorex’ an in-house codine based cough syrup brand for the first time in its history. received the Kenya PPB GMP approval from all facilities namely lozenges,liquids and ointments. Received registration for ‘Arecta Plus’(a lozenge variant of Viagra tablets)from Sierrs Leone and Libya; received the first export order for this product to be executed in 2012-2013.